STSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
STSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Satsuma Pharmaceuticals's enterprise value is $-4.79 Mil. Satsuma Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-64.24 Mil. Therefore, Satsuma Pharmaceuticals's EV-to-EBITDA for today is 0.07.
The historical rank and industry rank for Satsuma Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
During the past 6 years, the highest EV-to-EBITDA of Satsuma Pharmaceuticals was 22.53. The lowest was -4.07. And the median was 0.00.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-08), Satsuma Pharmaceuticals's stock price is $1.10. Satsuma Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-2.010. Therefore, Satsuma Pharmaceuticals's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Satsuma Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Satsuma Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | - | -8.69 | -0.32 | -0.99 | 0.32 |
Satsuma Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -0.76 | -1.05 | -2.17 | 0.32 | 0.28 |
For the Biotechnology subindustry, Satsuma Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Satsuma Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Satsuma Pharmaceuticals's EV-to-EBITDA falls into.
Satsuma Pharmaceuticals's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | -4.786 | / | -64.239 | |
= | 0.07 |
Satsuma Pharmaceuticals's current Enterprise Value is $-4.79 Mil.
Satsuma Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Satsuma Pharmaceuticals (NAS:STSA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Satsuma Pharmaceuticals's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 1.10 | / | -2.010 | |
= | At Loss |
Satsuma Pharmaceuticals's share price for today is $1.10.
Satsuma Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Satsuma Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Mutya Harsch | director | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Shin Nippon Biomedical Laboratories, Ltd. | 10 percent owner | 2438 MIYANOURA-MACHI, KAGOSHIMA CITY, KAGOSHIMA M0 891-1394 |
Thomas P Soloway | director | C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108 |
Ken Takanashi | director, 10 percent owner | C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138 |
Braden Michael Leonard | 10 percent owner | 156 S. FIRST STREET, ZIONSVILLE IN 46077 |
Commodore Capital Lp | 10 percent owner | 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022 |
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Peter Kolchinsky | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Management, L.p. | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Detlef Albrecht | officer: Chief Medical Officer | SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080 |
Thomas P. O'neil | officer: Chief Financial Officer | SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080 |
Rajeev M. Shah | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Tpg Group Holdings (sbs) Advisors, Inc. | 10 percent owner | C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102 |
Heath Lukatch | director | 326 BOLLAY DRIVE, GOLETA CA 93117 |
John A Kollins | director, officer: President and CEO | SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Value_Insider Value_Insider • 12-20-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By PurpleRose PurpleRose • 07-10-2022
By sperokesalga sperokesalga • 04-17-2023
By GuruFocusNews GuruFocusNews • 06-20-2022
By Value_Insider Value_Insider • 11-03-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By GuruFocusNews GuruFocusNews • 06-27-2022
By GuruFocusNews GuruFocusNews • 07-07-2022
By PRNewswire PRNewswire • 05-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.